Menu

rss
Evid Based Nurs doi:10.1136/ebnurs-2011-100480
  • Women's health
  • Cohort study

Risk of venous thromboembolism in oral contraceptive users varies according to progestin type

  1. Susan S Jick
  1. Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts, USA
  1. Correspondence to Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 1 Muzzey Street, Lexington, MA 02421, USA; sjick{at}bu.edu

Commentary on: Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343:d6423.

Implication for practice and research

  • ■ Combined oral contraceptives (OCs) increase the risk of venous thromboembolism (VTE).

  • ■ The risk of VTE in users of OCs containing desogestrel, gestodene, cyproterone and drospirenone is around twice that of levonorgestrel OCs users.

  • ■ Differences in VTE risk should be taken into consideration when prescribing OCs.

Context

Oral contraceptives first introduced in the 1960s contained high doses of estrogen and progestin. These were associated with increased risk for cardiovascular disease (CVD), including VTE, and high estrogen dose was thought to be responsible.1 In subsequent years, OCs containing lower estrogen doses and different …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. ebnurs-2011-100480v1
    2. 15/3/82 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

EBN Twitter Journal Club

The club runs like other journal discussion groups, except that the article and questions are posted on this blog and the discussion about the article happens on Twitter.

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.